The pharmacokimtics of aztronam, a monocyclic 3-lactam which inhibits most members of the family Enterobacteriaceae at concentrations of <1 g/mil and m6Wt Psekdomonas aerugit*sa isolates at concentrations of <16 pg/ml, were examined in healthy malq volunteers after 30-mn intravenous infusions of 0.5, 1, and 2g -of the drug. Mean peak levels of the drug in serum at the end of infusin wbr 65.5, 164, and255 nil afer 0.5, 1, and 2 g, respectively, with levels of the druoi serum of 1.8, 3, and 8.5 pg/l at 8.5h for the three doses, respectively.
inhibitory concentration for P. aefulmosa isolates for 4 h.
Aztreonam is a monocyclic 3-lactam anibiotic which has been shown-to-have activity against the majoity of gram-negative aerobic bactenia. It inhibits the 'norty of the members of the family Enterobacteriaceae at concentrations of <1 ,g/ml and most Pseudomonas aeruginosa isolates at concentrations of <16 Ftg/ml (8, 10, 15) . With this in vitro activity, aztreonam has promise in the therapy of infections due to organisms resistant to older cephalosporins and to aminoglycosides. Previous studies of the pharmacology of aztreonam have been performed with bolus intravenous administration of aztreonam or by the intramuscular route (13) . In the United States, most antimicrobial agents are administered by infusion; therefore, we wished to determine the pharmocokinetic parameters of aztreonam after infusion over 30 min in accordance with standard clinical practice. We also wished to compare the pharmacokinetics of aztreonam with other new cephalosporins which had been studied in our laboratory (2, 5, 6, 9, 11, 12 (2, 9) . Antibiotic standards for assay of serum samples were prepared in pooled normal human serum from the subjects who had been shown to lack antibacterial activity against the assay organisms. Urine 
RESULTS
The results of the infusion of the three doses are given in Table 1 . At the end of infusion of 0.5, 1, and 2 g of aztreonam, the mean concentrations of the drug in serum were 65.5, 164, and 255 ,ug/ml, respectively. Mean levels of the drug in serum of 14, 35 , and 67 ,ug/ml were present 2 h after the end of infusion (2.5 h after the beginning of infusion). At 4 h after dosing, aztreonam levels were 7.0, 16, and 36 jig/ml, whereas at 8 h, levels of 1.8, 3, and 8.5 p,g/ml were present.
Even at 12 h after the end of infusion, aztreonam could be detected, and levels of 0.92 and 1.87 ,ug/ml were found after the 1-and 2-g doses, respectively.
The pharmacokinetic characteristics of the three infusions are noted in Table 2 . There was rapid distribution of the compound after all three doses. The calculated serum half-life of the drug ranged from 1.90 0.21 h for the 1-g dose to 2.16 ± 0.38 h for the 2-g dose. These differences were not statistically significant. The various volumes of distribution, particularly the calculated apparent volume of distribution at the steady state, were similar for all three doses. Serum clearance of aztreonam was similar for all doses, with values of 1.08 ± 0.14, 0.91 ± 0.06, Fig. 1 . There was 37 to 40% recovery of te drug in the 0-to 2.5-h period (which incltuded 0.3 h of drug infusion). By 12.5 h, recovery of the drug frm urine was 57 65, and 60% folkIhe 0.5-, a-ad 2-g doses, respectively.
Meap con*entatOns of the dug in urine and ranges of vaIles ars given in Table 3 . These valties raned fm meap levels of 5 ml, including isolates resistant to ampiclllh, carbenicillin, cefazolin, and cefamandole (8, 10, 15) . Equally important, the minimal bactericidal concentrations for the majority of bacterial isolates are within a single dilution of the minimal inhibitory concentrations (MICs). Aztreonam inhibits Haemophilus influenzae at concentrations of -<0.1 g/ml. Furthermore, it inhibits most P. aeruginosa isolates at concentratibns of <16 pg/mI, including carbenicillin-resistant isolates (8, 10) . In a recent clinical study, all P. aeruginosa isolates tested were inhibited oy 12.5 pg of atreonam per ml (B. Scully and H. C. Neu, manuscript in preparation).
The phrmaology of aztreonam shown it this study was compared 'with the MICs of blood culture ibites during the past 2 years in our laboratory (Fig. 2) . After a 1-g dose, levels of aztreonam in serum remain well above the MICs ANTIMICROB. AGENTSCHEMOTHER. 
